
Jayakrishna Ambati, MD, discusses phase 2 K8 findings in geographic atrophy, inflammasome targeting and K8 dosing and delivery.
September was one of the busiest months of the year in eye care—From ESCRS to Eyecon
ESCRS 2026 brought thousands of anterior segment specialists to London, EyeCon 2026 put optometrists and ophthalmologists at the same table, and a steady stream of trial readouts and regulatory decisions kept the pipeline moving. Here is what our editors and contributors covered.





